Aspivix
- Company typePrivate
- Founded2017
- HeadquartersRenens, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Aspivix firmographics
Firmographics- Name
- Aspivix
- Legal name
- Aspivix SA
- Website
- https://aspivix.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Aspivix industry classification
Industry- Product category
- Gynecological Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy) (HLAKAJAF)
- akta.pro secondary industry
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
Keywords
Where Aspivix is headquartered
LocationHeadquarters
- HQ city
- Renens
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Aspivix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Medical Device Sales: Sale of carevix cervical stabilizers to healthcare providers (hospitals, clinics, OBGYN practices) and potentially direct-to-consumer through FSA/HSA reimbursement pathway in the US market.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Aspivix product offering
Product offeringCore offering
Aspivix develops, manufactures, and commercializes the carevix® Suction Cervical Stabilizer, a single-use medical device that uses suction technology to atraumatically stabilize the cervix during transcervical gynecological procedures such as IUD insertion. The device replaces the traditional century-old cervical tenaculum and is sold to hospitals, OBGYN clinics, and healthcare providers, with FDA clearance (K223866), CE marking, and authorization in the UK and Brazil.
Product overview
Aspivix is a single-product medical device company with carevix® as its core offering. Carevix® is a suction-based cervical stabilizer that serves as an atraumatic alternative to the century-old cervical tenaculum used in gynecological procedures. The device is specifically designed to reduce pain and bleeding during IUD insertion and other transcervical procedures. The company has achieved regulatory clearances in multiple markets (FDA, CE, UK, Brazil) and is focused on modernizing gynecology practices through evidence-based innovation.
Differentiator
Problem solved
Functional benefit
Brands
- carevix: Suction Cervical Stabilizer - A next-generation, suction-based cervical device clinically proven to reduce pain and bleeding during transcervical procedures such as IUD insertion.
Products and services
- carevix® Suction Cervical Stabilizer A single-use, suction-based cervical stabilizer that atraumatically secures the cervix during transcervical procedures such as IUD insertion, replacing the century-old sharp-hook cervical tenaculum. It is designed for OBGYNs, gynecologists, and healthcare providers performing IUD insertions and other transcervical gynecological interventions. FDA-Cleared (K223866), CE-Marked, and authorized in the UK and Brazil.
Quantifiable outcome
- 94% patient satisfaction rate in post-marketing study of 1,123 IUD procedures
- +6 more outcomes
Companies that use Aspivix
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
Aspivix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Aspivix partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- CHUV LausannecoreUniversity hospital in Lausanne, Switzerland serving as a key clinical study site. Prof. Patrice Mathevet, Chief Gynecologist, is an Aspivix study investigator.
- HUG GenevacoreHôpitaux Universitaires de Genève (Geneva University Hospitals) listed as a partner organization supporting research and clinical activities.
- VenturelabminorSwiss startup support organization that selected Aspivix for Venture Leaders Life Sciences 2018 program.
- MassChallengeminorGlobal startup accelerator; listed as an Aspivix partner organization.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Aspivix competitors and assessment
Company assessmentBroad incumbents
- CooperSurgical: Large women's health medical device company and the established manufacturer of the traditional cervical tenaculum that carevix displaces. CooperSurgical operates the broad OBGYN instrument portfolio and distribution channels Aspivix must compete against or partner with.
- Hologic: Large women's health diagnostics and medical device incumbent with extensive OBGYN sales channels. Hologic is a logical strategic acquirer and a benchmark for commercial-scale women's health device companies.
- Organon: Global women's health company with a portfolio spanning contraception, fertility, and menopause. Organon has the OBGYN commercial reach and franchise rationale to be a strategic acquirer of carevix.
Direct peers
- Minerva Surgical: US-focused gynecology medical device company developing minimally invasive solutions for abnormal uterine bleeding and other transcervical/intrauterine procedures. Highly comparable in product category, target clinician (OBGYN), and commercial-stage focus.
- Gynesonics: Gynecology-focused medical device company with transcervical and intrauterine procedures products (e.g., Sonata system for fibroid treatment). Directly comparable niche medtech serving OBGYNs with procedure-specific disposable devices.
- Caldera Medical: Women's pelvic health medical device company focused on stress urinary incontinence and pelvic organ prolapse products sold to OBGYNs and urogynecologists. Comparable in product category (single-use OBGYN devices) and customer base.
- Channel Medsystems: Women's health medical device company developing office-based solutions for gynecological conditions. Comparable in commercial-stage profile, OBGYN focus, and procedure-specific device model.
Emerging players
- Medicines360: Women's health pharmaceutical and device company with the Liletta IUD, focused on expanding contraceptive access. Closely aligned with the IUD-procedure ecosystem that carevix supports, and a potential channel partner.
- Elidah (Elitone): Early-stage femtech medical device company developing non-invasive women's health devices. Comparable as a small, single-product women's health device company building an OBGYN-direct and patient-pull commercial model.
Others
- Bayer (Women's Health / IUD portfolio): Bayer manufactures leading IUD brands (Mirena, Kyleena, Skyla) and has strong interest in improving IUD insertion experience. As a major IUD incumbent, Bayer is a potential commercial partner or acquirer for carevix.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Aspivix social profiles
Digital presenceAspivix compliance and trust
Trust signalCompliance4 records
Aspivix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aspivix leadership team
Management profileNumber of profiles
Profiles4 records
Aspivix funding detail
Funding detailFunding overview
Funding rounds17 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aspivix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aspivix
What does Aspivix do?
Aspivix develops, manufactures, and commercializes the carevix® Suction Cervical Stabilizer, a single-use medical device that uses suction technology to atraumatically stabilize the cervix during transcervical gynecological procedures such as IUD insertion. The device replaces the traditional century-old cervical tenaculum and is sold to hospitals, OBGYN clinics, and healthcare providers, with FDA clearance (K223866), CE marking, and authorization in the UK and Brazil.
Is Aspivix a public or private company?
Aspivix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aspivix founded?
Aspivix was founded in 2017. It employs 1 to 10 people.
Where is Aspivix based?
Aspivix is headquartered in Renens, Switzerland, in the Europe region.
How does Aspivix make money?
One revenue line is on record: medical Device Sales.
Who are Aspivix's main competitors?
Broad incumbents on record are CooperSurgical, Hologic and Organon. Direct peers are Minerva Surgical, Gynesonics, Caldera Medical and Channel Medsystems. Emerging players are Medicines360 and Elidah (Elitone). Bayer (Women's Health / IUD portfolio) is listed as an others.
Does Aspivix have an API?
No public API is recorded for Aspivix.
What industry is Aspivix in?
Aspivix's product category is Gynecological Medical Devices. Its primary akta.pro industry code is HLAKAJAF, Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy), with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.